Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
1
25%
Ph not_applicable
2
50%
Ph phase_2
1
25%

Phase Distribution

1

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
1(25.0%)
N/ANon-phased studies
2(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(4)

Detailed Status

Completed4

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (25.0%)
Phase 21 (25.0%)
N/A2 (50.0%)

Trials by Status

completed4100%

Recent Activity

0 active trials
Showing 4 of 4
completednot_applicable

High Dose Chemotherapy Followed By PBSC Rescue for HD

NCT00186251
completednot_applicable

Enrichment & Purging of Stem Cells in Non-Hodgkin's Lymphoma

NCT00186355
completedphase_2

Autologous Stem Cell Rescue for Primary Amyloidosis

NCT00186407
completedphase_1

CD34 Selection of the Peripheral Blood Stem Cell Graft for Autologous Transplant

NCT00186680

Clinical Trials (4)

Showing 4 of 4 trials
NCT00186251Not Applicable

High Dose Chemotherapy Followed By PBSC Rescue for HD

Completed
NCT00186355Not Applicable

Enrichment & Purging of Stem Cells in Non-Hodgkin's Lymphoma

Completed
NCT00186407Phase 2

Autologous Stem Cell Rescue for Primary Amyloidosis

Completed
NCT00186680Phase 1

CD34 Selection of the Peripheral Blood Stem Cell Graft for Autologous Transplant

Completed

All 4 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
4